Cancer, Diabetes Mellitus, Type 2
Conditions
Brief summary
The purpose of this study is to test a nurse-led intervention for adults with newly diagnosed cancer and undiagnosed/newly diagnosed Type-2 diabetes
Detailed description
Specific Aim 1: To examine study feasibility of a nurse-led intervention for adults with newly diagnosed cancer and T2D. We define feasibility indicators as: (a) efficient study recruitment is possible given prevalence of T2D (diagnosed and undiagnosed) in UF patients with newly diagnosed cancer; (b) retention rates in both groups ≥80% to indicate that the study design and methods are adequately patient-centered; (c) identified barriers to and facilitators of a nurse-led intervention are respectively modifiable or optimizable; and (d) patient acceptability scores \>8 for the study procedures. We hypothesize that we will recruit up to 40 patients within 18 months and retain ≥ 80% of patients in all groups; minor but important revisions will be required to resolve issues identified with using the nurse-led intervention; and 80% of patients from both groups who complete the study will report that the burden of the study is acceptable through their retention in the study. Specific Aim 2: To determine the variation in HbA1c at baseline and at the end of the three-month intervention period in each of the two study groups.
Interventions
OTHERNurse-led diabetes care
Nurse-led brief diabetes education, instructions on glucometer and Metformin use, patients receive prescriptions for Metformin and blood glucose testing kit
Sponsors
University of Florida
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* a) 18 years and older * b) Using pathology reports, a new diagnosis of a solid tumor cancer or lymphoma within the past 3 months * c) Patients being treated with curative intent or those with a prognosis estimated to be \>2 years, as best assessed by the oncologist. * d) First medical oncology outpatient visit at UF within the past 3 months * e) Plans to continue cancer care at UF * f) Speaks and reads English * g) Can comply with study related procedures, per the treating oncologist or advanced practice provider
Exclusion criteria
* a) Diagnosis of leukemia or pancreatic cancer as the new cancer diagnosis * b) Being treated for T2D for \> than 3 months * c) eGFR \<45mL/minute/1.73m2 * d) Liver insufficiency (defined as liver enzymes over 5 times the upper limit of normal or clinical sequelae of advanced cirrhosis as documented by the treating oncologist or Advanced Practice Providers. * e) Active infection requiring systemic antibiotics * f) Taking systemic steroids of more than 1-week duration. Must have stopped \>3 days prior to study enrollment. Note, inhaled or topical steroids are not
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acceptability | At 3-month study visit | Study acceptability (scores\>8 indicate adequate acceptability) will be measured via the Study Acceptability Scale questionnaire for both groups |
| Point of Care HbA1c Test | At baseline visit and at 3-month study visit | To determine the variation in HbA1c at baseline and at the end of the three-month intervention period in each of the two study groups. |
Countries
United States
Outcome results
None listed